Related Experiment Video
Updated: Nov 20, 2025

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
Published on: August 1, 2018
Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology
Alexander Kamyshnyi1, Inna Krynytska2, Victoriya Matskevych3
1Department of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
Insights
Arterial hypertension (AH) is a common comorbidity in COVID-19 patients, potentially worsening outcomes. Further research is needed on mechanisms like ACE2 and immune response, and the role of AH-linked ACE2 gene polymorphisms.
Area of Science:
- Cardiology
- Infectious Diseases
- Genetics
Background:
- COVID-19, caused by SARS-CoV-2, presents significant global health challenges.
- Arterial hypertension (AH) is a prevalent comorbidity in COVID-19 patients, associated with poorer outcomes and increased ICU admission.
- The precise mechanisms linking AH to adverse COVID-19 prognosis remain unclear.
Purpose of the Study:
- To explore the potential mechanisms connecting arterial hypertension and COVID-19 severity.
- To highlight the importance of blood pressure control and monitoring in hypertensive COVID-19 patients.
- To investigate the role of ACE2 and immune dysregulation in the context of AH and SARS-CoV-2 infection.
Main Methods:
- Review of current clinical data and existing literature on COVID-19 and arterial hypertension.
- Analysis of the proposed roles of angiotensin-converting enzyme 2 (ACE2) in both AH pathophysiology and SARS-CoV-2 infection.
- Examination of immune system dysregulation, including cytokine storms and T helper cell imbalance, in relation to AH and COVID-19.
Main Results:
- Arterial hypertension is a frequent comorbidity in COVID-19, linked to worse clinical outcomes.
- Potential mechanisms include the involvement of the ACE2 pathway and immune system dysregulation (cytokine storm).
- The specific impact of AH-linked ACE2 gene polymorphisms on SARS-CoV-2 infection risk and severity requires further investigation.
Conclusions:
- Optimizing blood pressure control is crucial for hypertensive patients during COVID-19 infection.
- Close monitoring for cardiovascular and other complications is essential for this patient group.
- Further research into the genetic and immunological links between AH and COVID-19 is warranted to improve patient management and outcomes.
Abstract:
Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is an ongoing global public health challenge. Current clinical data suggest that, in COVID-19 patients, arterial hypertension (AH) is one of the most common cardiovascular comorbidities; it can worsen outcomes and increase the risk of admission to intensive care unit (ICU). The exact mechanisms through which AH contributes to the poor prognosis in COVID-19 are not yet clear. The putative relationship between AH and COVID-19 may be linked to the role of angiotensin-converting enzyme 2 (ACE2), a key element of the AH pathophysiology. Another mechanism connecting AH and COVID-19 is the dysregulation of the immune system resulting in a cytokine storm, mediated by an imbalanced response of T helper cells subtypes. Therefore, it is essential to optimize blood pressure control in hypertensive patients and monitor them carefully for cardiovascular and other complications for the duration of COVID-19 infection. The question whether AH-linked ACE2 gene polymorphisms increase the risk and/or worsen the course of SARS-CoV-2 infection should also receive further consideration.
More Related Videos
Related Concept Videos
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease I: Introduction
Hypertension and Regulation of Blood Pressure
Peripheral Artery Disease I: Introduction
Measurement of Blood Pressure

